Opportunities to Pursue a Cost and Differentiation Strategy in Life Sciences Organizations image
Article

Opportunities to Pursue a Cost and Differentiation Strategy in Life Sciences Organizations

Artificial intelligence (AI) is already delivering transformational business value across virtually every industry and business operating model. As companies race to integrate AI into their enterprise environment, AI is changing how they operate. Over the next few years, for example, enterprise investment levels in AI will begin to exceed information technology (IT) spend, and new executive roles with dedicated AI teams will emerge.

Home

Our Thinking

Opportunities to Pursue a Cost and Differentiation Strategy in Life Sciences Organizations

Executive summary

Over the past few years, Life Sciences companies have committed to cost and differentiation strategy to improving operational efficiencies and automation focusing on Digital Innovation. The goal is to work smarter through advanced automation and data-driven decision making throughout all organization’s business functions.

Achieving this commitment is a challenge because commercially available AI based intelligent solutions are still in their infancy as compared to other industries such as finance and consumer goods.

By implementing the following sample strategies, a company can support their cost and differentiation/optimization objectives in the following business areas:

1. Pharmacovigilance

Automate the entire PV Case Intake process to reduce human interaction and move towards a touch-less case submission environment. The reduced manual hours directly result in cost savings. This includes NLP to read an Adverse Event either within a form or an unstructured email, and intelligently submit the Adverse Event to the Safety Database in a specific structured format. The NLP engine also translates the text from 5 languages into a PV Case in English.

2. Medical affairs

Implement a KOL (Key Opinion Leader) platform which includes an AI engine to help users search for and engage with these leaders in a targeted scientific and advocacy capacity. The AI based tool can utilize big data from various unstructured data sources, and apply AI to support selecting the fit-for purpose individual based on therapeutic area, disease, location, number of research articles, publications etc. By selecting the right KOL based on data, the firm can reduce long-term costs and improve efficiencies through targeted engagement strategies.

AI capabilities of the KOL platform can be used to process social media data to infer positive and negative sentiment on a relevant therapeutic area or disease. This will help identify leading and current influencers based on reach, relevance, and resonance criteria.

3. Commercial

Due to the COVID pandemic, the Commercial team has an opportunity to adopt technology to fill the gaps in activities that were traditionally always conducted in-person. Running Advisory Boards can now be conducted via a virtual platform. The data collected can be processed through an intelligent AI based tool to conduct intelligent focused surveys. This will save on travel and hotel costs which add up significantly over an annual period.
Conclusion

Conclusion

The above examples address a combined strategy of cost and differentiation. Differentiation is not from an end-product standpoint but a combination of how AI can help differentiate the collective organization from the competition and attract the best of breed talent. These are just a few examples of how a data-driven and digital innovation-focused leadership strategy is being fulfilled and where opportunities for improvement exist.

Want to learn more?

Reach out to the Acquis team

Contact

Tags:

AI
Digital Transformation
Technology Strategy
Innovation
Strategy
AI
Technology
Life Sciences

Share

Keep Reading

Reflective glass skyscraper corner with distorted reflections of nearby buildings, creating a mosaic of urban architecture in warm tones.
Article

The Transparency Revolution: How AI Unlocks Portfolio Intelligence at Scale

Leading PE firms are using AI to eliminate data latency, reduce churn, and transform quarterly reviews into continuous portfolio intelligence.

Read More

Four business professionals in formal attire are standing in a modern office lobby. Two are shaking hands, smiling, while the others look on.
Article

Welcome to the Alliance Economy: The New Biopharma Operating Model

We are entering what can best be described as the Alliance Economy, an operating model defined not by linear development pipelines, but by an ecosystem of interdependent players working together to navigate the new biopharma reality.

Read More

A woman in a white suit presents data on large screens to a group of seated people in a modern conference room.
Article

The Hidden 30%: How Fragmented Procurement Drains Mid-Market Profits

Many mid-market organizations quietly lose 30–40% of potential savings to fragmented spending systems. While executives focus on strategic sourcing deals, thousands of disconnected transactions drain value across the business — creating a downstream crisis hiding in plain sight.

Read More